BRP-201 is a promising research candidate for the development of next-generation anti-inflammatory drugs and a novel, potent, and selective inhibitor of mPGES-1 (microsomal prostaglandin E2 synthase-1) with an IC50 value of 0.42 μM, targeting inflammatory diseases.